Name | Value |
---|---|
Revenues | 13.0K |
Cost of Revenue | 49.0K |
Gross Profit | -36.0K |
Operating Expense | 5,305.0K |
Operating I/L | -5,292.0K |
Other Income/Expense | 1,381.0K |
Interest Income | 0.0K |
Pretax | -3,911.0K |
Income Tax Expense | 0.0K |
Net Income/Loss | -3,918.0K |
BioSig Technologies, Inc. operates as a medical device company, specializing in the development of the PURE EP system. This proprietary product offers real-time evaluation of electrograms in electrophysiology, addressing challenges in signal acquisition for electrophysiologists. The system enhances intracardiac signal acquisition and diagnostic information for atrial fibrillation procedures, aiming to improve the efficiency of cardiac catheter ablation procedures. Additionally, the company has research agreements and strategic collaborations to develop novel therapies and AI solutions for its PURE EP systems.